Paul R Rhomberg
Overview
Explore the profile of Paul R Rhomberg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
112
Citations
1834
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Maher J, Huband M, Lindley J, Rhomberg P, Aronin S, Puttagunta S, et al.
Microbiol Spectr
. 2025 Feb;
13(3):e0189824.
PMID: 39907459
Sulopenem is an oral and intravenous penem antibiotic in clinical development for treatment of urinary tract and intra-abdominal infections caused by multidrug-resistant pathogens. This study evaluated antimicrobial activity of sulopenem...
2.
Winkler M, Rhomberg P, Fedler K, Huband M, Karr M, Kimbrough J, et al.
J Clin Microbiol
. 2024 Dec;
63(2):e0120724.
PMID: 39704519
is a common cause of pulmonary and invasive mold infections among immunocompromised hosts. Mortality in immunocompromised hosts with invasive infections (IAI) has been reported to be as high as 80%....
3.
Pfaller M, Carvalhaes C, Rhomberg P, Klauer A, Castanheira M
Open Forum Infect Dis
. 2024 Nov;
11(11):ofae532.
PMID: 39494454
The activity of isavuconazole and other triazoles against non- (non-AFM) causing invasive aspergillosis was evaluated. A total of 390 non-AFM isolates were collected (1/patient) in 2017-2021 from 41 hospitals. Isolates...
4.
Castanheira M, Deshpande L, Rhomberg P, Carvalhaes C
Antimicrob Agents Chemother
. 2024 Sep;
68(10):e0057024.
PMID: 39264189
We observed an increase in the frequency of among invasive candidiasis isolates in the 2022 SENTRY Antifungal Surveillance Program compared to prior years: ≤0.1% before 2018, 0.4%-0.6% from 2018 to...
5.
Reidenberg B, Jenkins S, Crandon J, Hurlburt E, Tan X, Rhomberg P, et al.
Antimicrob Agents Chemother
. 2024 Jun;
68(7):e0038124.
PMID: 38864612
is an evolving and concerning global threat. Of particular concern are bloodstream infections related to central venous catheters. We evaluated the activity of taurolidine, a broad-spectrum antimicrobial in catheter lock...
6.
Pfaller M, Carvalhaes C, Rhomberg P, Castanheira M
Future Microbiol
. 2023 Nov;
19:173-180.
PMID: 38018423
What Is This Summary About?: Molds are types of fungus that can invade humans. It can cause a disease called invasive mold infection (IMI) and make people sick or cause...
7.
Pfaller M, Carvalhaes C, DeVries S, Rhomberg P, Castanheira M
Future Microbiol
. 2023 Oct;
19:85-90.
PMID: 37861300
What Is This Summary About?: Previous research shows that patients with COVID-19 have a high chance of getting fungal infections. Medicines called antifungals are used to treat fungal infections. However,...
8.
Pfaller M, Carvalhaes C, Deshpande L, Rhomberg P, Castanheira M
J Fungi (Basel)
. 2023 Jun;
9(6).
PMID: 37367544
Azole resistance in (AFM) is mainly associated with mutations in CYP51A and its promoter region or its homologue CYP51B. We evaluated the in vitro activity of isavuconazole, itraconazole, posaconazole, and...
9.
Carvalhaes C, Rhomberg P, Huband M, Pfaller M, Castanheira M
J Fungi (Basel)
. 2023 Feb;
9(2).
PMID: 36836355
Isavuconazole is the only US FDA-approved antifungal for treating invasive mucormycosis. We evaluated isavuconazole activity against a global collection of Mucorales isolates. Fifty-two isolates were collected during 2017-2020 from hospitals...
10.
Carvalhaes C, Rhomberg P, Pfaller M, Locke J, Castanheira M
Mycoses
. 2022 Jul;
65(11):1040-1044.
PMID: 35778886
Rezafungin, a new echinocandin with an extended half-life, exhibits potent activity against Candida spp. Aside from the MIC, specific interactions between antifungal and isolate, including the duration of anti-infective activity,...